<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511313</url>
  </required_header>
  <id_info>
    <org_study_id>SNP-CT-1601</org_study_id>
    <nct_id>NCT03511313</nct_id>
  </id_info>
  <brief_title>Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension</brief_title>
  <official_title>A Prospective, Multi-centers, Randomized, Controlled Study of Assessing the Safety and Efficacy of Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synaptic Medical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synaptic Medical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of renal denervation with
      sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension
      in China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in daytime average systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>from baseline to 3 months post-procedure</time_frame>
    <description>Primary effective outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in office systolic blood pressure</measure>
    <time_frame>from baseline to 3 months post-procedure</time_frame>
    <description>Secondary effective outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classes of anti-hypertensive medicine taken by participants</measure>
    <time_frame>6 months post-procedure</time_frame>
    <description>Secondary effective outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of achieving target office systolic blood pressure (office SBP&lt;140mmHg)</measure>
    <time_frame>from 3 months post-procedure to 6 months post-procedure</time_frame>
    <description>Secondary effective outcome measure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>from baseline to 3 months post-procedure and 6 months post-procedure</time_frame>
    <description>Safety outcome assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of renal stenosis</measure>
    <time_frame>6 months post-procedure</time_frame>
    <description>Safety outcome assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Other acute and chronic safety evaluating by the incidence of major adverse event</measure>
    <time_frame>6 months post-procedure</time_frame>
    <description>Safety outcome assessment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Primary Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal angiography</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Renal angiography and maintaining anti-hypertensive medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal denervation</intervention_name>
    <description>After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.</description>
    <arm_group_label>Renal denervation</arm_group_label>
    <other_name>Renal angiography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Renal angiography</intervention_name>
    <description>A renal angiography according to standard procedure.</description>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_label>Renal angiography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individual is ≥18 years and ≤65 years old.

          -  Primary hypertension.

          -  Screen criteria: Individual who received a stable anti-hypertensive medication regimen
             including 2 or more anti-hypertensive medications of different classes prior to
             screening, and at the initial screening visit, he has an office systolic blood
             pressure(SBP)≥ 150mmHg, and ≤180mmHg, is entering the screening period after writing
             the informed consent. Individual is receiving a 4week standard dose of amlodipine
             besylate (Norvasc) and Losartan Potassium and Hydrochlorothiazide tablets (HYZAAR®),
             and has a SBP≥150mmHg and＜180mmHg at the second week after screening, and has an
             Ambulatory 24-hour daytime average systolic blood pressure monitoring ≥140mmHg and
             ＜170mmHg at the fourth week after screening.

        Exclusion Criteria:

          -  Secondary hypertension.

          -  History of prior renal artery intervention including balloon angioplasty or stenting.

          -  Renal artery stenosis (≥50%) in either renal artery.

          -  Main renal arteries with ＜4mm, or &gt;8mm in diameter.

          -  Main renal arteries with ＜20mm in length.

          -  Estimated glomerular filtration rate (eGFR) of &lt;40 ml/(min•1.73m2).

          -  History of Stroke or TIA within 6 months prior to screening period.

          -  History of Acute coronary syndrome within 6 months prior to screening period.

          -  Structural heart disease without receiving effective treatment; Coronary heart disease
             with β blockers; severe peripheral artery disease that affecting blood pressure
             measurement and other unqualified conditions evaluated by investigator.

          -  Heart failure (NYHA classification Ⅲ-Ⅳ).

          -  Coagulation disorders associated with significant bleeding tendency, and history of
             other blood system diseases.

          -  History of cancer.

          -  Type 1 diabetes mellitus; Type 2 diabetes mellitus with target organ injuring.

          -  Acute or severe systemic inflammatory response syndrome.

          -  Any other serious medical condition unqualified to participate in this study evaluated
             by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Huo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiayi Wang</last_name>
    <phone>+86-18511291205</phone>
    <email>jiayi.wang@synapticmed.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Liu</last_name>
    <phone>+86-18701241121</phone>
    <email>qing.liu@synapticmed.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanhua Wang</last_name>
      <phone>+86-010-66119205</phone>
      <email>jgbgs090101@126.com</email>
    </contact>
    <investigator>
      <last_name>WEI Ma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Hypertension</keyword>
  <keyword>Renal Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

